NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PGEN
Precigen, Inc.
There isn't enough reported data to score PGEN yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PGEN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
PGEN's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over PGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
PGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.2x | $4.66 | — |
| Cheap | 7.9x | $0.55 | -88% |
| Fair | 9.5x | $0.66 | -86% |
| Expensive | 14x | $0.98 | -79% |
| Current | 67x | $4.66 | — |
Historical ranges are pointers, not guarantees.
PGEN's PE is 67x, but its earnings don't support one, so it isn't a reliable read right now.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
PGEN has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PGEN on earnings, with more consistent year-over-year improvement.
PGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | +829% |
| Q3 2026 | $0.07 | +$1.45 |
| Q2 2026 | -$1.07 | -$0.66 |
| Q1 2026 | -$1.21 | -$0.66 |
| Q4 2025 | -$1.37 | -$0.90 |
| Q3 2025 | -$1.38 | -$0.83 |
| Q2 2025 | -$0.41 | +$0.13 |
| Q1 2025 | -$0.55 | -$0.16 |
| Q4 2024 | -$0.47 | -$0.08 |
PGEN has returned to profit: it earned $0.07 per share over the past year, after losing money the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
PGEN has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus up 3,906% for PGEN.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
PGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $1.8M | -39% |
| Q1 2023 | $1.9M | -94% |
| Q4 2022 | $1.8M | -93% |
| Q3 2022 | $16.7M | -22% |
| Q2 2022 | $2.9M | -91% |
| Q1 2022 | $32M | +31% |
| Q4 2021 | $24.2M | +25% |
| Q3 2021 | $21.6M | -8.6% |
PGEN's revenue is growing: $74M last quarter, up 3906% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 52% | N/A |
| Q2 2026 | 41% | N/A |
| Q1 2026 | -26% | N/A |
| Q2 2023 | -1154% | -255 points |
| Q1 2023 | -1231% | -1171 points |
| Q4 2022 | -1257% | -1154 points |
| Q3 2022 | -46% | +93 points |
| Q2 2022 | -898% | -838 points |
PGEN has the edge over NVO on profitability, with a higher operating margin.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
PGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +$40.9M |
| Q2 2026 | -$18.2M | +$1.7M |
| Q1 2026 | -$44.1M | -$27.1M |
| Q4 2025 | -$23.5M | -$14.2M |
| Q3 2025 | -$29.5M | -$5.8M |
| Q2 2025 | -$19.9M | +$5.5M |
| Q1 2025 | -$16.9M | +$1.5M |
| Q4 2024 | -$9.3M | +$7.5M |
PGEN has burned cash in almost every quarter: −$74M over the past year, against −$76M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +7.5M shares |
| 1 year | +37% | +114M shares |
| 3 years | +69% | +173M shares |
| 5 years | +112% | +222M shares |
| Available history | +173% | +267M shares |
PGEN has 421M diluted shares, up 37% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PGEN Net Leverage
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 23.8 | Neutral |
PGEN's weekly RSI is 43 (neutral) and its Stochastic is 24 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over PGEN on valuation relative to its sector.
PGEN PE vs Healthcare Sector
| Metric | PGEN | Sector median | Relative |
|---|---|---|---|
| PE | 67x | 26x | 158% above |
| PE % | 100 | 29 | 71 pts above |
PGEN is trading at 67x earnings, a 158% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.59 | 29% below |
| 20 week MA | $6.48 | 28% below |
| 50 week MA | $5.10 | 8.6% below |
| 100 week MA | $3.68 | 27% above |
| 200 week MA | $2.48 | 88% above |
PGEN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.74 | $10.0 | +75% |
| 2021 | $10.0 | $4.10 | -59% |
| 2022 | $4.10 | $1.40 | -66% |
| 2023 | $1.40 | $1.34 | -4.3% |
| 2024 | $1.34 | $0.73 | -46% |
| 2025 | $0.73 | $4.16 | +470% |
| 2026 YTD | $4.16 | $4.66 | +12% |
PGEN has the edge over NVO on returns for 2026, with the stronger performance.